{"title":"Systemic association of myelin oligodendrocyte glycoprotein antibody disease: A systematic review of literature","authors":"Camelia Porey, B. Jaiswal","doi":"10.1111/ncn3.12790","DOIUrl":null,"url":null,"abstract":"Association of MOGAD with various autoimmune and paraneoplastic antibodies has been described in the literature. However, MOGAD with systemic manifestations is rarely encountered and requires a high index of suspicion for evaluation. Searching various databases, we identified 107 studies. After independently assessing the eligibility, finally, 29 studies were selected for review. A total of 1458 MOG patients were included in the study among whom systemic manifestations were present in 253 (17.3%) patients. SLE with ANA positivity was found in a total of 72 (28.4%) patients. Among them, anti‐dsDNA was positive in 10 (3.9%), anti‐smith in 3 (1.2%), anti‐SSA/SSB in 13 (5.1%), anti‐RNP in 3 (1.1%), anti‐Ro 52 in 1 (0.5%), and ENA in 1 (0.5%). APLA was positive in 10 (3.9%), ANCA in 10 (3.9%), RA in 31(12.9%) and thyroid antibody in 35 (13.8%) patients. Simultaneous CNS and PNS involvement was also seen in 21 (8.3%) patients. Systemic involvement is not an uncommon phenomenon in MOGAD and in future may add to the spectrum of the disease.","PeriodicalId":19154,"journal":{"name":"Neurology and Clinical Neuroscience","volume":"28 16","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology and Clinical Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/ncn3.12790","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Association of MOGAD with various autoimmune and paraneoplastic antibodies has been described in the literature. However, MOGAD with systemic manifestations is rarely encountered and requires a high index of suspicion for evaluation. Searching various databases, we identified 107 studies. After independently assessing the eligibility, finally, 29 studies were selected for review. A total of 1458 MOG patients were included in the study among whom systemic manifestations were present in 253 (17.3%) patients. SLE with ANA positivity was found in a total of 72 (28.4%) patients. Among them, anti‐dsDNA was positive in 10 (3.9%), anti‐smith in 3 (1.2%), anti‐SSA/SSB in 13 (5.1%), anti‐RNP in 3 (1.1%), anti‐Ro 52 in 1 (0.5%), and ENA in 1 (0.5%). APLA was positive in 10 (3.9%), ANCA in 10 (3.9%), RA in 31(12.9%) and thyroid antibody in 35 (13.8%) patients. Simultaneous CNS and PNS involvement was also seen in 21 (8.3%) patients. Systemic involvement is not an uncommon phenomenon in MOGAD and in future may add to the spectrum of the disease.